Alessandro Testolin
Research Subjects
Research Interests
Alessandro Testolin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Gava
Department of Radiation Oncology, Azienda Ospedaliera ULSS 9, 31100 Treviso, Italy
1 shared publication - Carlo Cavedon
Medical Physics Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
1 shared publication - Cristina Baiocchi
Radiation Oncology Unit, San Bortolo Hospital, Vicenza, Italy
1 shared publication - Filippo Alongi
Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Negrar, 37024 Verona, Italy
1 shared publication - Francesco Fiorica
Department of Clinical Oncology, Section of Radiation Oncology and Nuclear Medicine, AULSS 9 Scaligera, 37122 Verona, Italy
1 shared publication - Gabriele Nube
Controllo di Gestione e Adempimenti, LEA Unit, Veneto Region, Italy
1 shared publication
Latest Publications
- 26 November 2020
- Published by Springer Nature in La radiologia medica
- Vol. 126 (4) , 623-629
Radiotherapy activities and technological equipment in Veneto, Italy: a report from the Rete Radioterapica Veneta
Background Despite the pivotal role of radiotherapy in oncology, the provision of radiation treatments remains inadequate in many areas of the world. The present report is an assessment conducted among Radiation Oncology centers of Veneto region with the aim to collect information concerning radiotherapy assets and technological equipment availability. Methods Data concerning Veneto Radiation Oncology departments about radiotherapy activities, number of treatments, techniques used and radiotherapy machines available were collected. The reference time period was 2018. Reimbursement system databases and business intelligence systems were used. Extra-regional attraction and migration were evaluated. When available, data were compared to previous years. Results Veneto in 2018 was endowed with 1 megavolt unit for about 153,000 inhabitants. The number of megavolt machines per million inhabitants resulted to be 6.72. In 51% of radiotherapy treatments, intensity-modulated techniques were performed. Six percent of treatments were administered to extra-regional patients. Conclusion Radiotherapy assets and equipment in Veneto seem to be appropriate to standard requests in terms of availability and technology.
- 26 November 2020
- Published by Springer Nature in La radiologia medica
- Vol. 126 (4) , 623-629
Radiotherapy activities and technological equipment in Veneto, Italy: a report from the Rete Radioterapica Veneta
Background Despite the pivotal role of radiotherapy in oncology, the provision of radiation treatments remains inadequate in many areas of the world. The present report is an assessment conducted among Radiation Oncology centers of Veneto region with the aim to collect information concerning radiotherapy assets and technological equipment availability. Methods Data concerning Veneto Radiation Oncology departments about radiotherapy activities, number of treatments, techniques used and radiotherapy machines available were collected. The reference time period was 2018. Reimbursement system databases and business intelligence systems were used. Extra-regional attraction and migration were evaluated. When available, data were compared to previous years. Results Veneto in 2018 was endowed with 1 megavolt unit for about 153,000 inhabitants. The number of megavolt machines per million inhabitants resulted to be 6.72. In 51% of radiotherapy treatments, intensity-modulated techniques were performed. Six percent of treatments were administered to extra-regional patients. Conclusion Radiotherapy assets and equipment in Veneto seem to be appropriate to standard requests in terms of availability and technology.
- 1 November 2015
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 88 (1055) , 20150228
Stereotactic body radiation therapy for a new lung cancer arising after pneumonectomy: dosimetric evaluation and pulmonary toxicity
Objectives:To evaluate the tolerance of stereotactic body radiation therapy (SBRT) for the treatment of secondary lung tumors in patients who underwent previous pneumonectomy.Methods:12 patients were retrospectively analyzed . The median maximum tumour diameter was 2.1 cm (1-4.5). The median planning target volume (PTV) was 20.7 cm3 (2.4-101.2). Five patients were treated with a single fraction of 26 Gy and 7 with fractionated schemes (3x10 Gy, 4x10 Gy, 4x12 Gy). Lung toxicity, correlated with volume (V) of lung receiving more than 5, 10 and 20 Gy, local control and survival rate were assessed. Median follow up was 28 months.Results:none of the patients experienced pulmonary toxicity > 2 at the median dosimetric lung parameters of V5 , V10 and V20 of 23 % (range 10.7-56.7), 7.3 % (2.2-27.2) and 2.7 % (0.7-10.9) respectively. No patients required oxygen or had deterioration of the performance status during follow up if not as a result of clinical progression of disease. The local control probability at 2 y...
- 1 November 2015
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 88 (1055) , 20150228
Stereotactic body radiation therapy for a new lung cancer arising after pneumonectomy: dosimetric evaluation and pulmonary toxicity
Objectives:To evaluate the tolerance of stereotactic body radiation therapy (SBRT) for the treatment of secondary lung tumors in patients who underwent previous pneumonectomy.Methods:12 patients were retrospectively analyzed . The median maximum tumour diameter was 2.1 cm (1-4.5). The median planning target volume (PTV) was 20.7 cm3 (2.4-101.2). Five patients were treated with a single fraction of 26 Gy and 7 with fractionated schemes (3x10 Gy, 4x10 Gy, 4x12 Gy). Lung toxicity, correlated with volume (V) of lung receiving more than 5, 10 and 20 Gy, local control and survival rate were assessed. Median follow up was 28 months.Results:none of the patients experienced pulmonary toxicity > 2 at the median dosimetric lung parameters of V5 , V10 and V20 of 23 % (range 10.7-56.7), 7.3 % (2.2-27.2) and 2.7 % (0.7-10.9) respectively. No patients required oxygen or had deterioration of the performance status during follow up if not as a result of clinical progression of disease. The local control probability at 2 y...